Multifunctional Biomaterial Coatings for Blood-Contacting Thrombosis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing biomaterials used in blood-contacting medical devices suffer from uncontrolled protein adsorption leading to thrombosis due to rapid platelet adhesion and coagulation, despite current surface modification strategies like heparin immobilization and fibrinolytic treatments, which are limited in efficacy.
Innovation Solution
A biomaterial surface is modified with a polymerizable dopamine-containing bioadhesive to which antithrombotic agents such as anticoagulant, fibrinolytic, and antiplatelet agents are attached, forming a dual-functional coating to inhibit clot formation and promote clot lysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single surface modification strategies (heparin immobilization) are applied to polymers, then anticoagulant function is provided, but efficacy is limited and thrombosis is not sufficiently reduced
Solution Approach 1:
The patent combines multiple antithrombotic agents (heparin, hirudin, t-PA, aspirin) into a single surface modification coating on the biomaterial. This merging of multiple functional agents addresses the limitation of single-agent modifications by providing comprehensive antithrombotic protection through anticoagulant, antiplatelet, and fibrinolytic mechanisms simultaneously.
Solution Approach 2:
The surface modification system is designed to perform multiple functions: anticoagulation (heparin), direct thrombin inhibition (hirudin), fibrinolysis (t-PA), and antiplatelet activity (aspirin). This multi-functional coating resolves the contradiction by making the surface modification universally effective against multiple thrombotic pathways.
2Adaptability or versatility
If fibrinolytic surface modifications (t-PA incorporation) are applied, then ability to lyse fibrin clots is provided, but overall antithrombotic efficacy remains insufficient
Solution Approach 1:
The patent merges fibrinolytic agents (t-PA) with anticoagulant agents (heparin, hirudin) and antiplatelet agents (aspirin) in a single surface coating. This combination ensures that while fibrinolytic function is provided, it works synergistically with other mechanisms to achieve reliable thrombosis reduction.
Solution Approach 2:
The surface modification creates a composite functional layer containing multiple types of antithrombotic molecules with different mechanisms of action. This composite approach enhances overall reliability by providing redundant and complementary protective mechanisms against thrombosis.
3Reliability
If antithrombin-heparin complex (ATH) is used, then longer half-life and higher inhibition rate are achieved, but comprehensive antithrombotic protection is still insufficient
Solution Approach 1:
The patent combines ATH (providing high inhibition rate) with additional agents including hirudin (direct thrombin inhibition), t-PA (fibrinolysis), and aspirin (antiplatelet). This merging expands the mechanism coverage beyond what ATH alone can provide, addressing the versatility deficiency while maintaining high inhibition efficacy.
Solution Approach 2:
The surface coating achieves universal antithrombotic protection by incorporating agents that target different thrombotic pathways: coagulation cascade inhibition (ATH, hirudin), fibrin clot lysis (t-PA), and platelet aggregation inhibition (aspirin). This multi-functional design resolves the contradiction between high inhibition rate and comprehensive mechanism coverage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified biomaterial surfaces effectively reduce thrombosis by preventing clot formation and promoting clot lysis, demonstrating enhanced antithrombotic activity compared to single-agent modifications.
Implementation Method 1
Oxidation occurs when dopamine is exposed to alkaline conditions in an aqueous solution. Following this, self-assembled PDA layers form on organic or inorganic surfaces in contact with the solution.
Implementation Method 2
Following this, self-assembled PDA layers form on organic or inorganic surfaces in contact with the solution.
Implementation Method 3
A biomaterial surface is modified with a polymerizable dopamine-containing bioadhesive to which antithrombotic agents such as anticoagulant, fibrinolytic, and antiplatelet agents are attached
Data Source
AI summary
An antithrombotic surface-modified biomaterial is provided comprising a biomaterial substrate coated with a polymerizable dopamine-containing bioadhesive to which is attached one or more antithrombotic agents. A method of preparing the surface-modified biomaterial is also provided. The surface-modified biomaterial is beneficial for use in blood-contacting medical devices such as catheters, dialyzers and blood oxygenators to prevent or minimize the occurrence of thrombosis on the surface thereof.